Eli Lilly's experimental gene-editing therapy VERV-102 achieved a 62% reduction in cholesterol levels at the highest dose in Phase 1 clinical trials. The single-dose treatment targets the PCSK9 gene to potentially provide permanent cholesterol control. β Photo by Supplements On Demand on Pexels (Pexels License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, AccrΓ©ditation Sans FrontiΓ¨res (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016β2021). ORCID: 0000-0001-7609-4515.
